Leading gene therapy company uniQure N.V.
It has not been a good day for investors this Thursday. Worries about trade, the situation in Saudi Arabia, plunging oil prices, falling …
Hartaj Singh believes QURE trots out an upper hand advantage with AMT-061.
Uniqure NV is back in the race for a hemophilia B gene therapy.
Leerink analyst Michael Schmidt provides a second-quarter recap for shares of Uniqure NV (NASDAQ:QURE), reiterating an Outperform rating with a $27 price target, …
Uniqure NV (NASDAQ:QURE), a leader in human gene therapy, today announced the appointment of Jonathan Garen as Chief Business Officer. Mr.
Uniqure NV (NASDAQ:QURE), a leader in human gene therapy, announced financial results for the first quarter ending March 31, 2016, and provided a …
uniQure NV (NASDAQ:QURE), a leader in human gene therapy, announced the data from several preclinical research programs focused on the development and validation …
Uniqure NV (NASDAQ:QURE), a leader in human gene therapy, announced audited results for the fourth quarter and year ending December 31, 2015, and …
Uniqure NV (NASDAQ:QURE), a leader in human gene therapy, today announced the publication of preclinical data supporting its proprietary Huntington’s disease gene therapy …
